We are currently updating the OP Help Center content for the release of OP 14.19 or OP 19. OP 19 is a member of the certified OP 14 family of products (official version is 14.19.1), which you may see in your software (such as in Help > About) and in the Help Center tabs labeled 14.19. You may also notice that the version number in content and videos may not match the version of your software, and some procedural content may not match the workflow in your software. We appreciate your patience and understanding as we make these enhancements.

Office Practicum 14.6.22

Office Practicum 14.6.22

Previous Next

Release Date: 08-Sep-2017

Release Version and Build: Office Practicum Version 14.6 Build 14.6.22


Flu Season Information
For CDC guidelines regarding the 2017-2018 flu season, click here.
To access the FAQ page for the 2017-2018 flu season, click here.
For CDC guidelines regarding the 2016-2017 flu season, click here.
For general 2017-2018 flu season information, click here.
For Pediatrics-specific 2017-2018 flu season information, click here.
For AAP's Flu Vaccine Recommendations for 2017-2018, click here.


Closure of Customer Support Issues
If an entry in these release notes is the result of a client's call to customer support and that issue was logged in our issue-tracking system, the Solution ID for that issue is included at the beginning of the solution or resolution.

New Features

Non Function-specific New Features

There are no new features in this release that impact the overall application.

Function-specific New Features

There are no new features in this release that impact a specific function.

Improved Functionality

Non Function-specific Improved Functionality

There is no improved functionality in this release that impacts the overall application.

Function-specific Improved Functionality

Patient Chart / Immunizations and Utilities / Manage Codes / Vaccine Products

Function:
OP 14 needs to update the list of manufacturers, NDC codes, and CVX codes to match the latest vaccine information for the 2017-2018 flu season.
Solution:
Enhanced the software by updating the vaccine information to ensure that it reflects the latest list of manufacturers, NDC codes, and CVX codes related to vaccines for the 2017-2018 flu season. This helps to ensure OP 14 provides accurate vaccine inventories and vaccine names and to simplify the end user’s task of identifying and administering the latest vaccines for the end user.
This data maps NDC (1D barcodes) and/or GTIN (2D barcodes) to the associated OP 14 Vaccine Name, Manufacturer, and CVX code. This enhancement benefits the vaccine intake staff, so that, when they swipe a barcode or manually enter an NDC/GTIN, OP 14 automatically populates all other vaccine values correctly and automatically.
Here are some additional links to assist you in navigating the 2017-2018 flu season:
* Click here for details on the Vaccines for Children Program (VFC).
* Click here for details on IIS: HL7 Standard Code Set (Mapping CVX to Vaccine Groups).
* Click here for details on IIS: HL7 Standard Code Set (Mapping Product Names to CVX and MVX).
* Click here to access the GS1 Check Digit Calculator, which allows you o check the last digit on a bar code.
Note:  This enhancement completes functionality begun in version OP 14.6.19.

Patient Chart / Immunizations and Utilities / Manage Codes / Vaccine Products 

Function:
The vaccine name in OP 14 for the meningococcal Group B vaccine needs to be changed in order for VacLogic to differentiate between the original 3-dose series and the subsequently approved 2-dose series.
Solution:
Enhanced the software to support the latest name changes for the MenB vaccine. These changes ensure that OP 14 supports both MenB series as follows:
* Three-dose schedule: Administer a dose (0.5 mL) at 0, 1--2, and 6 months.’
* Two-dose schedule: Administer a dose (0.5 mL) at 0 and 6 months. If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose.
Note:  The choice of dosing schedule may depend on the risk of exposure and the patient's susceptibility to meningococcal serogroup B disease. Based on this statement, the doctor would determine the patient’s risk of exposure before giving the first MenB-FHbp immunization and then order either a 2 dose or 3 dose series.
For details, visit the MenB Name Changes page.

Resolved Issues

Non Function-specific Resolved Issues

There are no resolved issues in this release that impact the overall application.

Function-specific Resolved Issues

There are no resolved issues in this release that impact a specific function.

Known Critical Issues

There are no known issues in this release.